<DOC>
	<DOCNO>NCT00981149</DOCNO>
	<brief_summary>Temporomandibular joint disorder ( TMJD ) family musculoskeletal disorder represent common chronic orofacial pain condition . TMJD associate persistent pain region temporomandibular joint muscle head neck . The purpose study test duloxetine ( Cymbalta ) potential treatment chronic facial pain . Duloxetine FDA approve antidepressant chronic pain condition fibromyalgia diabetic neuropathy . Chronic facial pain may link Temporomandibular Joint Disorder ( TMJD ) currently standard treatment .</brief_summary>
	<brief_title>Duloxetine Treatment Painful Temporomandibular Joint Disorder</brief_title>
	<detailed_description>The propose clinical trial evaluate analgesic adverse effect duloxetine , serotonin norepinephrine reuptake inhibitor , comparison placebo patient temporomandibular joint disorder ( TMJD ) . Duloxetine approve antidepressant show effective chronic pain condition fibromyalgia diabetic neuropathy . Decrease pain dysfunction improvement quality life global satisfaction assess 6 week . Successful demonstration therapeutic effect may provide basis clinical use duloxetine patient painful TMJD . Background TMJD heterogeneous family musculoskeletal disorder associate temporomandibular joint , periauricular region , muscle head neck . TMJD identify major cause nondental , chronic pain craniofacial region , second headache ( NIH Technology Assessment Conference , 1997 ) . Although population-based epidemiological study conduct , study report prevalence TMJD 20 % adult population ( Dworkin et al 1990 , Schiffman et al 1990 ) . Dworkin colleague conduct series study TMJD use valid reliable examination survey procedure ( Von Korff et al 1988 , Dworkin et al 1990 , Carlsson LeResche 1995 ) identify 12.1 % test population painful TMJD female male ratio approximately 7:1 . They also find annual incidence develop TMJD 2 % female tend show high incidence rate male ( Von Korff et al 1993 ) . Hence , TMJD common general population , also report 20 % patient early sign symptom TMJD progress persistent pain state ( Schiffman et al 1990 ) . Several study TMJD suggest patient exhibit state CNS hypersensitivity similar report fibromyalgia ( Maixner et al 1995 , Maixner et al 1998 , Sarlani Greenspan 2003 , Sarlani et al 2004 ) contribute predict widespread characteristic pain . Genetic factor impact increase pain sensitivity , psychological trait sex difference , often couple environmental stress , may result phenotype vulnerable musculoskeletal disease susceptible selective pharmacological treatment . In addition female gender , two factor predict elevate incidence disorder : history musculoskeletal pain body sit quality life symptom typically associate depression ( Von Korff et al 1988 , Raphael Marbach 2001 , John et al 2003 ) . Patients diagnose fibromyalgia often exhibit concurrent orofacial symptomatology mimic TMJD ( Ta et al 2002 , Sarlani Greenspan 2003 , Sarlani et al 2004 ) . These observation finding suggest drug useful depression , affect musculoskeletal system , effective improve central monoaminergic neurotransmission , prime candidate treatment TMJD . For reason , hypothesize selective noradrenergic combine noradrenergic serotonin reuptake inhibitor effective TMJD . Lack research result paucity evidence-based treatment approach TMJD ( Antczak- Bouckoms 1995 , List 2003 ) . While NSAIDs sometimes use , little evidence effectiveness TMJD ( Dionne 1997 , Gordon et al 1990 , 1991 ) except frank joint involvement ( Ta et al 2004 ) , gastrointestinal renal toxicity limit long-term use ( Gabriel et al 1991 , Allison et al 1992 , Schafer et al 1995 , Champion et al 1997 ) treatment chronic pain . Use opioids discourage chronic pain condition due limitation long-term use drug class ( DeNucci et al 1996 , Dionne 1997 ) . The promising pharmacologic therapy TMJD date antidepressant , important note indication clinical use primarily extrapolate chronic pain condition ( McQuay et al 1992 , Onghena et al 1992 ) . Only two randomize control trial examine one tricyclic antidepressant ( amitryptyline ) TMJD specifically ( Sharav et 1987 , Rizzatti-Barbosa 2003 ) . Amitryptyline TMJD demonstrate average response rate 40 % two study , adverse effect result large percentage patient discontinue drug achieve pain relief ( DeNucci et al 1996 ) , result unfavorable risk benefit ratio ( Zitman et al 1990 ) . Taken together , insufficient evidence adopt pharmacologic standard care treatment TMJD . Duloxetine show efficacy several chronic pain condition ( Sultan 2008 ) include fibromyalgia , appear effective woman men ( Arnold 2004 , 2005 ) . It well tolerate effective dose 60 mg daily ( Sultan 2008 ) . Studies patient fibromyalgia ( Arnold 2004 , 2005 ) , diabetic neuropathy ( Goldstein 2005 ) , low back pain ( Skijaravala 2008 ) , osteoarthritis ( Chappell 2008 ) show analgesic effect dose few adverse effect low drop rate high dos . In proposed study , subject randomize intervention use 60 mg duloxetine give 30 mg twice daily one-week period 30 mg daily . Given prevalence TMJD controversial nature non-pharmacologic therapy occlusal alteration , intraoral device , surgery , need exist pharmacologic treatment efficacious avoids adverse effect discourage long-term use . This study also provide basis future investigation etiology management painful TMJD . Purpose/Objective study ? TMJD represent prototypic musculoskeletal disease whose characteristic associate depression , comorbidity fibromyalgia , female prevalence , increase CNS sensitivity pain , likely genetic difference among susceptible individual , make disorder likely responsive duloxetine treatment.The overall objective investigate duloxetine potential treatment chronic pain TMJD . We hypothesize subject receive duloxetine experience great analgesia receive placebo . Specifically : 1 . Evaluate analgesic effect 30 mg duloxetine twice daily comparison match placebo baseline ( BL ) follow six week period use primary outcome measure change spontaneous pain . 2 . Evaluate jaw function evoke pain measure range motion , pain jaw movement , pain pressure threshold . 3 . Assess frequency adverse effect impact patient global satisfaction study adherence . 4 . Examine sleep relationship pain . 5 . Evaluate genetic susceptibilty pain response duloxetine . These aim outcome measure list prioritized order . The study power primary outcome measure spontaneous pain ; measure exploratory . The study power detect subgroup difference variable gender , depression , type TMJD diagnosis , concurrent medication , describe later Analysis Plan . Research Design : The study double blind , placebo-controlled parallel group prospective study duloxetine versus placebo . Subjects randomize investigational treatment group ( duloxetine ) placebo group . At time enrollment randomly assign study drug placebo block randomization order 1:1 ratio . Subjects provide acetominophen rescue analgesic use feel pain adequately control . The examiner subject blind group assignment .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Joint Diseases</mesh_term>
	<mesh_term>Temporomandibular Joint Disorders</mesh_term>
	<mesh_term>Temporomandibular Joint Dysfunction Syndrome</mesh_term>
	<mesh_term>Duloxetine Hydrochloride</mesh_term>
	<criteria>Patients chronic TMJD pain two week duration Age 18 old Confirmed craniofacial pain nonodontogenic origin Research Diagnostic Criteria temporomandibular disorder ( TMDRDC ) Concomitant medication permit , except may convey analgesia Females neither pregnant , verify urinebased pregnancy test , breastfeed Female subject childbearing potential postmenopausal le 2 year must using/willing use medically approve method contraception ( i.e. , oral , transdermal implant contraceptive device , intrauterine device , diaphragm , condom , abstinence , surgical sterility course study Able read comprehend rating scale , study instruction , consent form Pain score 4 great baseline VAS ( 010 ) Undergone type TMJ surgery TMJ growth disturbance , neoplasm , injury TMJ area within past six month Taking analgesic antiinflammatory drug , steroid , antidepressant , antiepileptic , opioid medication may confound assessment analgesia Subjects primary psychiatric diagnosis major depression , suicidal ideation , history suicide attempt assess medical history Mini International Neuropsychiatric Interview ( MINI ) eligible . Subjects score average high comparison normative score Beck Depression Inventory ( BDI ) allow participate Exclusions base effect duloxetine : Known hypersensitivity duloxetine inactive ingredient Subjects : renal impairment end stage renal disease ; urinary retention hesitation , delay gastric emptying ; substantial alcohol use evidence chronic liver disease , hepatic insufficiency hepatotoxicity ; bleed disorder , orthostatic hypotension , uncontrolled high blood pressure ; recent history myocardial infarction unstable coronary artery disease ; seizure disorder , history bipolar disorder mania , general anxiety disorder ( GAD ) ; hyponatremia ; uncontrolled narrowangle glaucoma . Treatment monoamine oxidase inhibitor ( MAOI ) within 30 day randomization , potential need use MAOI study within 5 day discontinuation drug Concomitant use medication : NSAIDs , warfarin , aspirin drug affect coagulation ; Thioridazine inhibitor CYP1A2 affect metabolism duloxetine ; serotonergic drug like triptans MAOIs increase risk Serotonin Syndrome ; drug affect gastric acidity Contraindications acetaminophen use Ever treat duloxetine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>